Major Law Firm Probes Four Corporate Deals Over Shareholder Value Concerns

Halper Sadeh LLC, a prominent investor rights litigation firm, has launched formal investigations into four separate corporate transactions, alleging that shareholders may not be receiving fair value and that company boards may have breached their fiduciary duties. The firm is examining transactions involving Sila Realty Trust ($SILA), Esperion Therapeutics ($ESPR), Corebridge Financial ($CRBG), and Equitable Holdings ($EQH), seeking to determine whether the deals represent adequate compensation for shareholders and whether all required disclosures have been provided.

The investigations center on three distinct transactions that have drawn scrutiny from securities counsel regarding process, valuation methodologies, and board oversight. These probes represent a critical juncture in how institutional investors and shareholder advocates scrutinize major M&A activity in an era of heightened corporate governance awareness.

Details of the Disputed Transactions

Sila Realty Trust's Sale to Blue Owl Affiliates

The investigation into $SILA concerns the real estate investment trust's sale to affiliates of Blue Owl Capital Partners, a major alternative asset manager. The firm is examining whether the transaction price adequately reflects the value of Sila's real estate portfolio and whether the board conducted a thorough, competitive process to solicit alternative bidders. Realty trust shareholders are particularly sensitive to valuation issues, as REITs are typically valued based on underlying property values and cash flow generation capacity.

Esperion Therapeutics' Acquisition by ARCHIMED

Esperion Therapeutics ($ESPR), a biopharmaceutical company focused on cardiovascular and metabolic diseases, agreed to be acquired by ARCHIMED, a European-based private equity and strategic investment firm. Halper Sadeh is investigating whether the acquisition price adequately compensates shareholders for the company's pipeline of drug candidates and future earnings potential. Biotech acquisitions are frequently contested because valuations depend heavily on the probability of clinical trial success and regulatory approval—variables that can be difficult to quantify.

Corebridge Financial and Equitable Holdings Merger

The merger between Corebridge Financial ($CRBG) and Equitable Holdings ($EQH) represents a significant consolidation within the insurance and financial services sector. This transaction has drawn particular attention because both companies operate in a highly regulated industry where shareholder value can be substantially affected by the terms of combination, including the exchange ratio, governance structure, and integration costs. The investigation seeks to determine whether the merger consideration is fair to both sets of shareholders and whether all material risks and synergies have been adequately disclosed.

Market Context and Governance Landscape

The Shareholder Activism and M&A Scrutiny Environment

The investigations by Halper Sadeh LLC reflect broader market trends in corporate governance and shareholder activism. Institutional investors, pension funds, and class action securities firms have intensified their scrutiny of major corporate transactions, particularly in instances where:

• Deal valuations appear below historical trading multiples or analyst estimates
• The sales process appears compressed or non-competitive
• Board members have potential conflicts of interest
• Complex structures obscure true economic value transfer

In recent years, numerous high-profile acquisitions have faced post-closing scrutiny or shareholder litigation, establishing legal precedents that encourage investment in rigorous transaction review. The fiduciary duty framework imposed on corporate boards requires them to act in good faith, with appropriate diligence, and with the goal of obtaining fair value for shareholders.

Sector-Specific Challenges

Each of the targeted sectors faces distinct valuation challenges:

• Real Estate: REIT transactions depend on property valuations, cap rates, and market dynamics that can shift rapidly, making fair value determination complex
• Biotechnology: Drug pipeline valuation requires probabilistic analysis of clinical success rates, regulatory timelines, and market adoption—subjective assessments vulnerable to disputes
• Insurance & Financial Services: Complex asset portfolios, liability structures, and regulatory capital requirements make merger pricing intricate

Investor Implications and What's at Stake

For Shareholders in Target Companies

If Halper Sadeh's investigations uncover evidence of inadequate valuations or board malfeasance, shareholders may have grounds for:

• Settlement payments providing additional consideration beyond the original transaction price
• Renegotiated transaction terms reflecting higher valuations
• Directors and officers liability claims
• Enhanced disclosure remedies requiring fuller information to shareholders

Historically, successful M&A litigation has resulted in price increases ranging from single-digit percentages to substantial upward adjustments, depending on the strength of evidence regarding board process failures and valuation shortcomings.

Broader Market Implications

These investigations underscore several important dynamics for investors and corporate management:

1. Increased Board Diligence Requirements: Companies undertaking major transactions face heightened expectations for documentation of fair value determinations, including valuations from multiple methodologies and engagement of independent financial advisors

2. Disclosure Standards: Boards must provide comprehensive disclosure regarding transaction processes, conflicts of interest, financial adviser communications, and risk factors

3. Market Pricing Risk: Acquirers and target company boards must contend with the possibility that announced transactions will face legal challenges, potentially delaying closing or requiring renegotiation

4. Institutional Investor Activism: Major shareholders increasingly engage legal counsel to review proposed transactions pre-closing, creating pressure on boards to demonstrate rigorous processes

Strategic Implications for Deal-Makers

For mergers and acquisitions professionals, these investigations highlight the importance of:

• Conducting thorough go-shop processes and actively soliciting competing bidders
• Engaging recognized financial advisers to provide fairness opinions
• Documenting board deliberations comprehensively
• Addressing potential conflicts of interest through special committees and independent directors
• Providing detailed disclosure regarding valuation methodologies and assumptions

Forward Outlook

The investigations by Halper Sadeh LLC into $SILA, $ESPR, $CRBG, and $EQH transactions represent the continuing evolution of shareholder protection mechanisms in American capital markets. As institutional asset managers control increasingly large equity positions, their legal representatives are more empowered to challenge transactions perceived as undervalued or poorly negotiated.

For investors holding positions in these companies or considering related investments, the legal outcomes remain uncertain but carry material financial implications. The firm's focus on both increased consideration and enhanced disclosures suggests a multifaceted approach to shareholder protection—seeking not only better pricing but also greater transparency in future transactions.

Corporate boards and deal advisers should view these investigations as part of an evolving regulatory and legal environment where M&A processes face heightened scrutiny. The investigations may ultimately result in settlements, price adjustments, or expanded disclosures, but they also reinforce that transaction processes perceived as deficient face substantial legal risk. Investors should monitor the progression of these investigations, as outcomes could affect not only the immediate parties but also market practices and expectations for future M&A activity.